- Home
- CASI vs ATNM Comparison
CASI vs ATNM Comparison
Compare CASI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- ATNM
- Stock Information
- Founded
- CASI 1991
- ATNM 2000
- Country
- CASI China
- ATNM United States
- Employees
- CASI N/A
- ATNM N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- ATNM Health Care
- Exchange
- CASI Nasdaq
- ATNM Nasdaq
- Market Cap
- CASI 35.0M
- ATNM 33.1M
- IPO Year
- CASI 1996
- ATNM N/A
- Fundamental
- Price
- CASI $2.21
- ATNM $1.15
- Analyst Decision
- CASI Strong Buy
- ATNM Strong Buy
- Analyst Count
- CASI 1
- ATNM 4
- Target Price
- CASI $6.00
- ATNM $8.75
- AVG Volume (30 Days)
- CASI 8.1K
- ATNM 150.7K
- Earning Date
- CASI 03-27-2025
- ATNM 04-25-2025
- Dividend Yield
- CASI N/A
- ATNM N/A
- EPS Growth
- CASI N/A
- ATNM N/A
- EPS
- CASI N/A
- ATNM N/A
- Revenue
- CASI $22,055,000.00
- ATNM $81,000.00
- Revenue This Year
- CASI N/A
- ATNM $138.42
- Revenue Next Year
- CASI $134.79
- ATNM $16,957.05
- P/E Ratio
- CASI N/A
- ATNM N/A
- Revenue Growth
- CASI N/A
- ATNM N/A
- 52 Week Low
- CASI $2.04
- ATNM $1.03
- 52 Week High
- CASI $7.67
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- CASI 35.91
- ATNM 48.84
- Support Level
- CASI $2.15
- ATNM $1.03
- Resistance Level
- CASI $2.49
- ATNM $1.16
- Average True Range (ATR)
- CASI 0.15
- ATNM 0.07
- MACD
- CASI 0.00
- ATNM 0.01
- Stochastic Oscillator
- CASI 35.42
- ATNM 52.38
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.